The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
Kratos Defense & Security Solutions (KTOS) is initiated with a Buy rating and a $135 price target, implying 92% upside from ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni ...
The Big Apple is about to be bled dry — and not just because of ferocious tax hikes. This spring and summer, NYC could see an ...
Boston)—Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global ...
The CDC is reporting that ER visits for tick bites are higher than usual. The CDC says that, according to its Bite Tracker, ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
Turkey’s trajectory is not dependent on the outcome of the Iranian case - it is a function of its desire to claim leadership ...
While every college admissions department evaluates applicants a bit differently, standardized test scores are a big piece of ...
Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality ...
The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...
The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results